ACP
RAPT

Acuta Capital Partners’s RAPT Therapeutics RAPT Stock Holding History

Acuta Capital Partners’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-25,036
Closed -$4.45M – 48
2021
Q1 		$4.45M Sell
25,036
-1,164
-4% -$192K 1.6% 28
2020
Q4 		$4.14M Sell
26,200
-3,800
-13% -$826K 1.13% 33
2020
Q3 		$7.73M Buy
+30,000
New +$6.66M 2.1% 17

Other funds holding RAPT

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return

Acuta Capital Partners's RAPT Position: Q2 2021 in Review

Acuta Capital Partners sold out of RAPT Therapeutics (RAPT) in Q2 2021, closing a stake of 25,036 shares — an estimated $4.45M sold.

Acuta Capital Partners first reported a position in RAPT in Q3 2020 and held it in 3 quarters. The position peaked at $7.73M in Q3 2020. 109 funds tracked by Wall St. Rank hold RAPT as of Q2 2021.

  • Acuta Capital Partners reported no remaining RAPT Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Acuta Capital Partners sold 25,036 RAPT Therapeutics shares in Q2 2021, an estimated $4.45M.
  • Acuta Capital Partners first reported a position in RAPT Therapeutics in Q3 2020 and held it in 3 quarters.
  • Acuta Capital Partners's RAPT Therapeutics position peaked at $7.73M in Q3 2020.
  • 109 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2021.

Based on Acuta Capital Partners's 13F filing for Q2 2021, filed 16 Aug 2021.